BLYS and IFN in SLE

The University of Alabama at Birmingham

Status: Completed

Conditions: Systemic Lupus Erythematosus

Treatments: Biological: pneumovax; Biological: fluzone

Study type: Observational

Funder types: Other

Identifiers

NCT00611611

NIH R21 AI069363

F060217005

Details and patient eligibility

About

This protocol tests whether changes in BLyS or IFN can be detected in a normal immune response to a vaccine and, if so, whether the response differs between those with lupus and healthy controls.

Enrollment: 39 patients

Sex: All

Ages: 19 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• ACR lupus criteria
• 18<age<65

Exclusion criteria

• chronic infection or cancer
• pregnancy

Trial design

39 participants in 2 patient groups

1

Description:

SLE

Treatment:

Biological: pneumovax

Biological: fluzone

2

Description:

healthy controls

Treatment:

Biological: pneumovax

Biological: fluzone